Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label single-arm canakinumab in Japanese adults with Adult Onset Still's Disease
jRCT2011200022Completed
- Sponsor
- Novartis
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of canakinumab in adult-onset Still's disease (AOSD), sponsored by Novartis. Primary endpoint: Adapted ACR30 response at Week 8. Started Mar 2021; status: completed.
02
Drugs
canakinumab
03
Conditions
adult-onset Still's disease (AOSD)
Beyond the preview
Go deeper on jRCT2011200022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011200022.